At least nine cancer therapeutics [monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors (TKIs)] targeting EGFR and/or HER2 are currently in clinical use [3, 9–13]. This evidence concerns the gene EGFR and cancer.